van de Donk NWCJ, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397:410–27.

Article  PubMed  Google Scholar 

Hanamura I. Multiple myeloma with high-risk cytogenetics and its treatment approach. Int J Hematol. 2022;115:762–77.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wolffe AP. Histone deacetylase: a regulator of transcription. Science. 1996;272:371–2.

Article  CAS  PubMed  Google Scholar 

Smith EM, Boyd K, Davies FE. The potential role of epigenetic therapy in multiple myeloma. Br J Haematol. 2010;148:702–13.

Article  CAS  PubMed  Google Scholar 

Berdeja JG, Laubach JP, Richter J, et al. Panobinostat from bench to bedside: rethinking the treatment paradigm for multiple myeloma. Clin Lymphoma Myeloma Leuk. 2021;21:752–65.

Article  CAS  PubMed  Google Scholar 

Harada T, Hideshima T, Anderson KC. Histone deacetylase inhibitors in multiple myeloma: from bench to bedside. Int J Hematol. 2016;104:300–9.

Article  CAS  PubMed  Google Scholar 

Ohguchi H, Hideshima T, Anderson KC. The biological significance of histone modifiers in multiple myeloma: clinical applications. Blood Cancer J. 2018;8:83.

Article  PubMed  PubMed Central  Google Scholar 

Imai Y, Hirano M, Kobayashi M, Futami M, Tojo A. HDAC inhibitors exert anti-myeloma effects through multiple modes of action. Cancers (Basel). 2019;11:475.

Article  CAS  PubMed  Google Scholar 

San-Miguel JF, Richardson PG, Günther A, et al. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol. 2013;31:3696–703.

Article  CAS  PubMed  Google Scholar 

Richardson PG, Schlossman RL, Alsina M, et al. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood. 2013;122:2331–7.

Article  CAS  PubMed  Google Scholar 

San-Miguel JF, Hungria VT, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014;15:1195–206.

Article  CAS  PubMed  Google Scholar 

Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007;109:31–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Whittaker SJ, Demierre MF, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010;28:4485–91.

Article  CAS  PubMed  Google Scholar 

Utsunomiya A, Izutsu K, Jo T, Yoshida S, et al. Oral histone deacetylase inhibitor tucidinostat (HBI-8000) in patients with relapsed or refractory adult T-cell leukemia/lymphoma: phase IIb results. Cancer Sci. 2022;113:2778–87.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rai S, Kim WS, Ando K, et al. Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results. Haematologica. 2023;108:811–21.

Article  CAS  PubMed  Google Scholar 

Abe F, Kitadate A, Ikeda S, et al. Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma. Oncotarget. 2017;8:7572–85.

Article  PubMed  Google Scholar 

Bartel DP. Metazoan MicroRNAs. Cell. 2018;173:20–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16:203–22.

Article  CAS  PubMed  Google Scholar 

Amodio N, Stamato MA, Gullà AM, et al. Therapeutic targeting of miR-29b/HDAC4 epigenetic loop in multiple myeloma. Mol Cancer Ther. 2016;15:1364–75.

Article  CAS  PubMed  Google Scholar 

Pichiorri F, Suh SS, Ladetto M, et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci USA. 2008;105:12885–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chi J, Ballabio E, Chen XH, et al. MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival. Biol Direct. 2011;6:23.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chang TC, Yu D, Lee YS, et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet. 2008;40:43–50.

Article  CAS  PubMed  Google Scholar 

Chou YT, Lin HH, Lien YC, et al. EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF. Cancer Res. 2010;70:8822–31.

Article  CAS  PubMed  Google Scholar 

Yu Z, Wei X, Liu L, et al. Indirubin-3’-monoxime acts as proteasome inhibitor: therapeutic application in multiple myeloma. EBioMedicine. 2022;78: 103950.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sanchez N, Gallagher M, Lao N, et al. MiR-7 triggers cell cycle arrest at the G1/S transition by targeting multiple genes including Skp2 and Psme3. PLoS One. 2013;8: e65671.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xiong S, Zheng Y, Jiang P, et al. PA28gamma emerges as a novel functional target of tumour suppressor microRNA-7 in non-small-cell lung cancer. Br J Cancer. 2014;110:353–62.

Article  CAS  PubMed  Google Scholar 

Tang S, Ma D, Cheng B, et al. Crucial role of HO-1/IRF4-dependent apoptosis induced by panobinostat and lenalidomide in multiple myeloma. Exp Cell Res. 2018;363:196–207.

Article  CAS  PubMed  Google Scholar 

Abe K, Ikeda S, Nara M, et al. Hypoxia-induced oxidative stress promotes therapy resistance via upregulation of heme oxygenase-1 in multiple myeloma. Cancer Med. 2023;12:9709–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Handa H, Murakami Y, Ishihara R, Kimura-Masuda K, Masuda Y. The role and function of microRNA in the pathogenesis of multiple myeloma. Cancers (Basel). 2019;11:1738.

Article  CAS  PubMed  Google Scholar 

Zhao J, Tao Y, Zhou Y, et al. MicroRNA-7: a promising new target in cancer therapy. Cancer Cell Int. 2015;15:103.

Article  PubMed  PubMed Central